XML 28 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 3 Months Ended 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Mar. 31, 2017
Mar. 31, 2016
Net revenues $ 41,575,480 $ 12,371,673 $ 57,427,701 $ 44,048,740
Costs and expenses        
Cost of services 40,239,642 10,133,005 48,735,537 34,000,786
General and administrative 4,889,184 3,836,475 18,583,372 16,962,687
Depreciation and amortization 155,267 164,658 645,742 351,396
Total costs and expenses 45,284,093 14,134,138 67,964,651 51,314,869
Loss from operations (3,708,613) (1,762,465) (10,536,950) (7,266,129)
Other (expense) income:        
Interest expense (192,989) (2,659) (82,905) (542,296)
Gain (loss) on change in fair value of warrant and conversion feature liabilities 0 822,222 1,633,333 (408,692)
Gain on deconsolidation of variable interest entity     242,411 0
Loss on debt extinguishment     0 (266,366)
Other income 38,657 1,971 14,701 239,057
Total other (expense) income, net (154,332) 821,534 1,807,540 (978,297)
Loss before benefit from income taxes (3,862,945) (940,931) (8,729,410) (8,244,426)
Benefit from income taxes (29,891) (41,553) (47,495) (71,037)
Net loss (3,833,054) (899,378) (8,681,915) (8,173,389)
Net loss (income) attributable to non-controlling interest 221,242 (415,879) 287,901 1,170,655
Net loss attributable to Apollo Medical Holdings, Inc. $ (3,611,812) $ (1,315,257) $ (8,969,816) $ (9,344,044)
Net loss per share:        
Basic and diluted $ (0.60) $ (0.22) $ (1.49) $ (1.79)
Weighted average number of shares of common stock outstanding:        
Basic and diluted 6,033,518 5,914,826 6,001,680 5,212,927